Democratizing CAR-T Therapies Globally
T-CURX is a German, venture backed, clinical-stage biotech company headquartered in Würzburg, with additional labs and offices in Munich, Bavaria, with a wholly-owned subsidiary, Pantherna-Therapeutics, in Brandenburg and Berlin (www.pantherna-therapeutics.com).
T-CURX has the ambition to democratize CAR-T cell therapies by leveraging its proprietary non-viral CAR-T cell technologies for developing in vivo CAR-T therapies, in order to make CAR-T therapies more accessible and affordable to cancer patients.
T-CURX CAR-T technology is based on T cell targeted LNP delivery of Sleeping Beauty transposon vectors allowing stable CAR expressing CAR-T cells in patients in vivo, in contrast to transient mRNA-based approaches, and without the need of complex, potentially immunogenic viral vector systems.
T-CURX is also pursuing clinical development of autologous, ex vivo CAR-T programs against a novel target, Siglec-6, in AML and CLL, and two additional follow-on CAR-T programs against non-disclosed targets, addressing novel cross-entity targets relevant for both hematological malignancies, as well as solid tumor indications.
T-CURX was spun-out from the academic research group of T-CURX co-founder Prof. Michael Hudecek (MD) University Hospital Würzburg, Germany, and was co-founded by Prof. Christoph Rader (PhD) (member of the scientific advisory board) amd Ulf Grawunder (PhD), who is serving as CEO of the company.
T-CURX is also supported by a syndicate of international investors, including BioMedVC as lead-investor, Highlight Capital, i&iBioFund and Bayernkapital as co-investors and also by scientific key opinion leaders and Biotech-industry veterans in T-CURX' Advisory Boards with proven track records in developing innovative medicines in the fields of immunology and cancer.
Partners and Business Development
Partners and Business Development